Top

Published in:

Open Access 01-12-2016 | Letter

Comment on: Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thicke AA, Tan MH, Tan PH. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Research 2016;18:31

Author: Joseph Loane

Published in: Breast Cancer Research | Issue 1/2016

Excerpt

I read with interest the article by Tan et al. [1] describing a five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions (FELs). …

Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thicke AA, et al. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Res. 2016;18:31.CrossRefPubMedPubMedCentral

Jacobs TW, Chen YY, Guinee DG, Eby PR, Thike AA, Vohra P, et al. Phyllodes tumor subsequent to a diagnosis of fibroadenoma on breast core needle biopsy: frequency and characteristics. In: USCAP 103rd annual meeting 2014; March 1–7 2014. San Diego, CA: Modern Pathology; 2014. p. 56A.

Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M, et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol. 2005;123(4):529–40.CrossRefPubMed

Jacobs TW, Chen Y-Y, Guinee JDG, Holden JA, Cha I, Bauermeister DE, et al. Fibroepithelial lesions with cellular stroma on breast core needle biopsy: are there predictors of outcome on surgical excision? Am J Clin Pathol. 2005;124(3):342–54.CrossRefPubMed

Lee AHS, Hodi Z, Ellis IO, Elston CW. Histological features useful in the distinction of phyllodes tumor and fibroadenoma on needle core biopsy of the breast. Histopathology. 2007;51(3):336–44.CrossRefPubMed

Title: Comment on: Tan WJ, Cima I, Choudhury Y, Wei X, Lim JCT, Thicke AA, Tan MH, Tan PH. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. Breast Cancer Research 2016;18:31
Author: Joseph Loane
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-016-0730-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems

Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study

The cell surface mucin podocalyxin regulates collective breast tumor budding

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer

Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer